Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T3P-Y058-739 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- T3 Pharmaceuticals
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
**T3P-Y058-739 + pembrolizumab** is an investigational combination therapy for advanced solid tumors. **T3P-Y058-739** is a genetically-modified, live attenuated strain of *Yersinia enterocolitica*, engineered to deliver therapeutic proteins into tumor cells via a type III secretion system (T3SS). This enables direct engagement and activation of the immune system through localized cytokine induction, promoting infiltration and activation of immune cells in the tumor microenvironment. The combination is being evaluated with **pembrolizumab**, a programmed cell death protein 1 (PD-1) checkpoint inhibitor, to potentially enhance anti-tumor immune responses by both mechanisms. The combination is under investigation in a phase I/II modular clinical study for patients with advanced solid malignancies[1][2][3][4][5][10].
- Other names
- T3P-Y058-739T-3P-Y058-739T 3P-Y058-739T3PT-3PT 3PpembrolizumabKeytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR (Toll-like receptors)
Beyond the preview
Go deeper on T3P-Y058-739 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T3P-Y058-739 + pembrolizumab.